# Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

> **NCT06257420** · — · ENROLLING_BY_INVITATION · sponsor: **Simmaron Research Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Myalgic Encephalomyelitis
- Long-COVID

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT06257420
- **Lead sponsor:** Simmaron Research Inc.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-12-11
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06257420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06257420, "Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06257420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*